Select your country
Websites worldwide
Select a country to go to the website of the respective STADA sales company.
Australia (1)
Austria (1)
Belarus (1)
Belgium (1)
Bosnia-Herzegovina (1)
Bulgaria (1)
China (1)
Croatia (1)
Czech Republic (2)
Denmark (1)
France (1)
Hungary (1)
Ireland (1)
Italy (1)
Montenegro (1)
Netherlands (2)
Poland (1)
Portugal (1)
Romania (1)
Saudi Arabia (1)
Serbia (1)
Slovakia (1)
Slovenia (1)
Spain (1)
Switzerland (1)
The Phillippines (1)
United Arab Emirates (1)
United Kingdom (3)
Vietnam (2)
STADA: domination and profit and loss transfer agreement pursuant to sections 291 et seqq. AktG concluded between STADA Arzneimittel AG and …
STADA Health Report 2017: Young adults lack health education
STADA shows good business development in the third quarter of 2017 and the first nine months
Luc Slegers to hand over responsibility for STADA Europe after 26 years
Frank Staud assumes overall responsibility for the STADA brand and communications
Dr. Claudio Albrecht appointed CEO and Mark Keatley CFO of STADA Arzneimittel AG
Supervisory Board of STADA Arzneimittel AG elects Dr. Günter von Au as new Chairman
STADA Annual General Meeting: Approval of the actions of the Executive Board for financial year 2016 postponed – guidance 2017 confirmed
Following the successful takeover vote for STADA: Members of the Supervisory Board to step down from their posts
Changes on the Supervisory Board of STADA Arzneimittel AG due to the takeover by Bain Capital and Cinven
Following the successful takeover vote for STADA: Members of the Supervisory Board to step down from their posts
Entering into negotiations of a domination and profit and loss pooling agreement between STADA Arzneimittel AG and Nidda Healthcare Holding …
STADA takeover offer by Bain Capital and Cinven successful
Minimum acceptance threshold for STADA takeover by Bain Capital and Cinven reached
STADA shows good operational development in first six months of 2017
Executive Board and Supervisory Board of STADA recommend acceptance of the renewed takeover offer by Bain Capital and Cinven
Bain Capital and Cinven publish offer document on the renewed voluntary public takeover offer for STADA Arzneimittel AG
STADA supports renewed improved takeover offer announced by Bain Capital and Cinven
Bain Capital and Cinven applied for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover of…
STADA Arzneimittel AG appoints new Chief Executive Officer and Chief Financial Officer – incumbents step down from their positions
Changes in the Executive Board of STADA Arzneimittel AG
STADA Arzneimittel AG confirms that Bain Capital and Cinven are considering to apply for an exemption from one-year exclusion period for the…
STADA Arzneimittel AG: Voluntary public takeover offer by Bain Capital and Cinven fails – STADA to continue pursuing successful growth strat…
STADA Arzneimittel AG: Voluntary public takeover offer by Bain Capital and Cinven not successful
STADA: Bain Capital and Cinven lower the minimum acceptance threshold for the takeover offer to STADA’s shareholders from 75 percent to 67.5…
Holger Pohlen is new Director of Media Relations at STADA Arzneimittel AG
STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG recommend acceptance of the voluntary public takeover offer by Bain Ca…
Interview with Dr. Matthias Wiedenfels on the occasion of the publication of the figures for the first quarter of 2017
STADA: Publication of the offer document on the voluntary public tender for STADA Arzneimittel AG by Bain Capital and Cinven
Dr. Ralph Grobecker to become Managing Director of STADA’s OTC segment
To the shareholders of STADA Arzneimittel AG: STADA supports voluntary public tender offer by Bain Capital and Cinven
STADA supports the voluntary public tender offer by Bain Capital and Cinven worth Euro 66.00 per share
STADA: Final figures for 2016 confirm good year-end results – medium term growth targets for 2019 raised
STADA postpones press and analyst conference on full year figures 2016
to March 29, 2017
STADA leverages positive momentum and raises targets for future-oriented program “STADA Plus”
STADA Arzneimittel AG confirms receipt of another non-binding expression of interest in takeover bid
STADA Supervisory Board establishes Ad Hoc Committee
STADA Arzneimittel AG confirms receipt of non-binding expressions of interest in takeover bid
Changes in the Executive Board of STADA Arzneimittel AG